VaIvular heart disease in patients taking pergolide

被引:149
作者
Pritchett, AM
Morrison, JF
Edwards, WD
Schaff, HV
Connolly, HM
Espinosa, RE
机构
[1] Mayo Clin, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin, Div Anat Pathol, Rochester, MN 55905 USA
[3] Mayo Clin, Div Cardiovasc Surg, Rochester, MN 55905 USA
关键词
D O I
10.4065/77.12.1280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine whether an association exists between pergolide and valvular heart disease. Patients and Methods: Three patients with severe, unexplained tricuspid regurgitation were examined at our institution from September 2000 to April 2002. Echocardiography and histology of surgically explanted valves revealed abnormalities suggestive of carcinoid involvement, methysergide or ergotamine treatment; or use of fenfluramine and dexfenfluramine. Carcinoid valvular heart disease was excluded. None of the patients had prior treatment with these drugs. All 3 patients were taking pergolide. Results: Of the 3 patients, 2 had predominantly right-sided congestive heart failure. In all 3 patients, echocardiography showed unusual valve morphology, with severe tricuspid valve regurgitation. Significant left-sided valve regurgitation was noted in 2 patients. Histologic analysis revealed surface fibroproliferative lesions with preserved underlying valve architecture. Conclusion: The echocardiographic and histopathologic features of these cases are strikingly similar to those associated with carcinoid-, ergot-, and fenfluramine-induced valve disease. An association between pergolide and valvular heart,disease may therefore exist.
引用
收藏
页码:1280 / 1286
页数:7
相关论文
共 27 条
[1]   CARDIAC MURMURS AND ENDOCARDIAL FIBROSIS ASSOCIATED WITH METHYSERGIDE THERAPY [J].
BANA, DS ;
MACNEAL, PS ;
LECOMPTE, PM ;
SHAH, Y ;
GRAHAM, JR .
AMERICAN HEART JOURNAL, 1974, 88 (05) :640-655
[2]   MOLECULAR-BIOLOGY OF 5-HT RECEPTORS [J].
BOESS, FG ;
MARTIN, IL .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :275-317
[3]  
BOWLER JV, 1986, LANCET, V2, P466
[4]   Practice parameters for the treatment of Restless Legs Syndrome and periodic limb movement disorder [J].
Chesson, AL ;
Wise, M ;
Davila, D ;
Johnson, S ;
Littner, M ;
Anderson, WM ;
Hartse, K ;
Rafecas, J .
SLEEP, 1999, 22 (07) :961-968
[5]   Valvular heart disease associated with fenfluramine-phentermine [J].
Connolly, HM ;
Crary, JL ;
McGoon, MD ;
Hensrud, DD ;
Edwards, BS ;
Edwards, WD ;
Schaff, HV .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (09) :581-588
[6]  
Connolly HM, 1999, CURR PROB CARDIOLOGY, V24, P751
[7]  
Fitzgerald LW, 2000, MOL PHARMACOL, V57, P75
[8]  
GRAHAM JR, 1967, AM J MED SCI, V254, P1
[9]   FIBROTIC DISORDERS ASSOCIATED WITH METHYSERGIDE THERAPY FOR HEADACHE [J].
GRAHAM, JR ;
SUBY, HI ;
LECOMPTE, PR ;
SADOWSKY, NL .
NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (07) :359-&
[10]  
HAUCK AJ, 1990, ARCH PATHOL LAB MED, V114, P62